TABLE I ______________________________________ MAT/P:Formulation mg/liter ______________________________________ Salts Ca(No.sub.3).sub.2.4H.sub.2O 50. CaCl.sub.2 58.3 Fe(No.sub.3).sub.3.9H.sub.2 O 0.25 KCl 355.9 MgSO.sub.4 (Anhydrous) 48.84 NaCl 6497.975 NaHCO.sub.3 1600. NaH.sub.2 PO.sub.4 (Anhydrous) 31.25 CuSO.sub.4.5H.sub.2 O 0.00065 FeSO.sub.4.7H.sub.2 O 0.2085 MgCl.sub.2 14.32 Na.sub.2 HPO.sub.4 435.51 ZnSO.sub.4.7H.sub.2 O 0.216 Other Components Sodium Hypoxanthine 1.195 Linoleic Acid 0.021 D-glucose 2575.5 Lipoic Acid 0.0525 Putrescine.2HCl 0.0405 Thymidine 0.1825 Phenol red 6.55 DL-Thioetic acid 0.525 Glutathione (reduced) 0.5 HEPES 1787.25 Sodium Pyruvate 27.5 Amino Acids L-Alanine 2.225 L-Asparagine 25. L-Asparagine.H.sub.2 O 3.75 L-Arginine free base l00. L-Arginine.HCl 326.55 L-Aspartic Acid 13.325 L-Cysteine.HCl.H.sub.2 O 8.78 L-Cystine 48. L-Cystine.2HCl 48.22 L-Glutamic Acid 13.675 Glycine 14.375 L-Histidine (free base) 7.5 L-Histidine.HCl.H.sub.2 O 99.74 L-Hydroxyproline l0. L-Isoleucine 157.235 L-Leucine 159.325 L-Lysine.HCl 210.625 L-Methionine 46.325 L-Phenylalanine 91.24 L-Proline 18.625 L-Serine 28.125 L-Threonine 131.925 L-Tryptophan 27.41 L-Tyrosine 72. L-Tyrosine.2Na 14.415 L-Tyrosine.2Na.2H.sub.2 O 27.875 L-Valine 130.025 Vitamins Biotin 0.10175 D-calcium pantothenate 1.245 Choline Chloride 5.99 Folic Acid 1.825 i-Inositol 23.8 Nicotinamide 0.5 Para-aminobenzoic acid 0.5 Pyridoxine.HCl 0.5155 Riboflavin 0.2095 Thiamine.HCl 1.585 Vitamin B12 0.3425 Niacinamide 1.01 Pyridoxal.HCl 1.0 Trace Elements MnCl.sub.2 0.5 nM (NH.sub.4).sub.6 Mo.sub.7 O.sub.24 0.5 nM NiSO.sub.4 0.25 nM H.sub.2 SeO.sub.3 15. nM Na.sub.2 SeO.sub.3 50. nM Na.sub.2 SiO.sub.3 250. nM SnCl.sub.2 0.25 nM NaVO.sub.3 2.5 nM CdSO.sub.4 50. nM Added at Time of Use - Unstable Components L-Glutamine 332.5 mg/L 2-mercaptoethanol 5 × 10.sup.-5 μM 2-aminoethanol (ethanolamine) 600 uM Transferrin l to 5 mg/L Insulin 5 mg/L ______________________________________
TABLE II __________________________________________________________________________CELL LINES THAT HAVE THE SAME GROWTH CHARACTERISTICS IN MAT/P AS IN FBS CONTAINING MEDIA: Cell Line Origin Length of Time Cultured __________________________________________________________________________Sarcomas (adherent) EMT6.S/Ro BALB/c spontaneous mammary sarcoma(g) 6 months & sublcones .2.1 (secretes immunosuppressive factor in MAT/P as in .8 FBS) each clone has differing growth .R.1 characteristics which are maintained in MAT/P .P Line 1 BALB/c spontaneous lung tumor(h) 6 months (Expresses H.sub.2 in response to DMSO in MAT/P as in FBS). Meth A.4 Methyl-cholanthrene induced sarcoma(i) 2 months (non-adherent variant) of BALB/c mice RIF-1 C3H radiation induced fibrosarcoma(j) 6 months WEHI 164 NC susceptible cell line of BALB/c mice(k) 4 months Hybridoma Lines M1/70.15.11.5 (anti-MAC-1) NS-1/rat spleen(a) 4 months GK1.5 (anti-L3/T4) SP2-0/rat spleen(b) 3 months AF3-12.1 (anti-H-2K.sup.K) SP2-0/BALB/c spleen(c) 3 months 53-6 (anti-Lyt 2) NS-1/rat spleen(d) 2 months T24/4017 (anti-Thyl) S194/5/Lewis rat spleen(e) 3 months MK-D6 (anti Ia.sup.K) P3X63/(C57B1/6xA/J)F.sub.1 (f) 3 months AF4-62.4 (anti-H-2D.sup.D) SP2-0/C3H(c) 4 months OR-689.2.4 P3/BALB/c spleen(r) 9 months (anti-opiate receptor) Lymphomas YAC-1 A/Sn T-cell lymphoma(1) 6 months EL4 C57BL/6 T-cell lymphoma(m) 4 months S49.1 T cell lymphoma(n) 1 month P815 DBA/2 Mastocytoma(o) 6 months Other Tumor Cell Lines NG108-15 Rat Neuroblastoma/glioma fusion(p) 1 month PC12 Rat pheochromocytoma(q) (chromaffin tumor) 1 month (differentiates in presence of NGF in MAT/P as in FBS containing media) Human Cell Lines HT 1080 Human Colon cancer 2 weeks __________________________________________________________________________ Note: Cultures were terminated at the times specified due to experimental desig rather than loss of growth potential.
______________________________________ mg/liter ______________________________________ Salts Ca(No.sub.3).sub.2.4H.sub.2 O 50. CaCl.sub.2 58.3 Fe(No.sub.3).sub.3.9H.sub.2 O 0.25 KCl 355.9 MgSO.sub.4 (Anhydrous) 48.84 NaCl 6497.975 NaHCO.sub.3 1600. NaH.sub.2 PO.sub.4 (Anhydrous ) 31.25 CuSO.sub.4.5H.sub.2 O 0.00065 FeSO.sub.4.7H.sub.2 O 0.2085 MgCl.sub.2 14.32 Na.sub.2 HPO.sub.4 435.51 ZnSO.sub.4.7H.sub.2 O 0.216 Other Components Sodium Hypoxanthine 1.195 Linoleic Acid 0.021 D-glucose 2575.5 Lipoic Acid 0.0525 Putrescine.2HCl 0.0405 Thymidine 0.1825 Phenol red 6.55 DL-Thioetic acid 0.525 Glutathione (reduced) 0.5 HEPES 1787.25 Sodium Pyruvate 27.5 Amino Acids L-Alanine 2.225 L-Asparagine 25. L-Asparagine.H.sub.2 O 3.75 L-Arginine free base 100. L-Arginine.HCl 326.55 L-Aspartic Acid 13.325 L-Cysteine.HCl.H.sub.2 O 8.78 L-Cystine 48. L-Cystine.2HCl 48.22 L-Glutamic Acid 13.675 Glycine 14.375 L-Histidine (free base) 7.5 L-Histidine.HCl.H.sub.2 O 99.74 L-Hydroxyproline 10. L-Isoleucine 157.235 L-Leucine 159.325 L-Lysine.HCl 210.625 L-Methionine 46.325 L-Phenylalanine 91.24 L-Proline 18.625 L-Serine 28.125 L-Threonine 131.925 L-Tryptophan 27.41 L-Tyrosine 72. L-Tyrosine.2Na 14.415 L-Tyrosine.2Na.2H.sub.2 O 27.895 L-Valine 130.025 Vitamins Biotin 0.10175 D-calcium pantothenate 1.245 Choline Chloride 5.99 Folic Acid 1.825 i-Inositol 23.8 Nicotinamide 0.5 Para-aminobenzoic acid 0.5 Pyridoxine.HCl 0.5155 Riboflavin 0.2095 Thiamine.HCl 1.585 Vitamin B12 0.3425 Niacinamide 1.01 Pyridoxa1.HCl 1.0 Trace Elements MnCl.sub.2 0.5 nM (NH.sub.4).sub.6 Mo.sub.7 O.sub.24 0.5 nM NiSO.sub.4 0.25 nM H.sub.2 SeO.sub.3 15. nM Na.sub.2 SeO.sub.3 50. nM Na.sub.2 SiO.sub.3 250. nM SnCl.sub.2 0.25 nM NaVO.sub.3 2.5 nM CdSO.sub.4 50. nM Added at Time of Use - Unstable Components L-Glutamine 332.5 mg/L 2-mercaptoethanol 5 × 10.sup.-5 μM 2-aminoethanol (ethanolamine) 600 uM Transferrin l to 5 mg/L Insulin 5 mg/L ______________________________________
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/774,114US4816401A (en) | 1985-09-09 | 1985-09-09 | Serum free cell culture medium |
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/774,114US4816401A (en) | 1985-09-09 | 1985-09-09 | Serum free cell culture medium |
Publication Number | Publication Date |
---|---|
US4816401Atrue US4816401A (en) | 1989-03-28 |
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/774,114Expired - LifetimeUS4816401A (en) | 1985-09-09 | 1985-09-09 | Serum free cell culture medium |
Country | Link |
---|---|
US (1) | US4816401A (en) |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5063157A (en)* | 1988-01-18 | 1991-11-05 | Boehringer Mannheim Gmbh | Serum-free culture medium for mammalian cells |
US5122469A (en)* | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5397706A (en)* | 1991-11-06 | 1995-03-14 | Correa; Paulo N. | Serum-free basal and culture medium for hematopoietic and leukemia cells |
US5405772A (en)* | 1993-06-18 | 1995-04-11 | Amgen Inc. | Medium for long-term proliferation and development of cells |
WO1995024467A1 (en)* | 1994-03-09 | 1995-09-14 | Cellco, Inc. | Serum-free production of packaged viral vector |
EP0719326A1 (en)* | 1993-08-23 | 1996-07-03 | Baxter International Inc. | $i(IN VITRO) GROWTH OF NEUTROPHIL AND MEGAKARYOCYTE PRECURSORS IN SERUM-FREE MEDIA |
US5540908A (en)* | 1992-11-19 | 1996-07-30 | The Trustees Of The Univ. Of Pennsylvania | Detection of hypoxia with reagents containing 2-nitroimidazole compounds and methods of making such reagents |
US5846529A (en)* | 1993-08-23 | 1998-12-08 | Nexell Therapeutics, Inc. | Infusion of neutrophil precursors for treatment of neutropenia |
US6037174A (en)* | 1993-08-23 | 2000-03-14 | Nexell Therapeutics, Inc. | Preparation of serum-free suspensions of human hematopoietic cells or precursor cells |
WO2000015224A1 (en)* | 1998-09-17 | 2000-03-23 | Eli Lilly And Company | Protein formulations |
US6048728A (en)* | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
US6051401A (en)* | 1998-07-28 | 2000-04-18 | Bayer Corporation | Methods and constructs for protein expression |
US6252087B1 (en) | 1992-11-19 | 2001-06-26 | The Trustees Of The University Of Pennsylvania | Nitroaromatic compounds for the detection of hypoxia |
US6573237B2 (en) | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
US6593140B1 (en) | 1992-07-24 | 2003-07-15 | Lonza Group, Ag | Animal cell culture |
US20030224001A1 (en)* | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
US20040006212A1 (en)* | 1995-06-07 | 2004-01-08 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
US20050026974A1 (en)* | 1996-02-08 | 2005-02-03 | Trustees Of The University Of Pennsylvania | Detection of hypoxia |
US6855828B1 (en) | 1992-11-19 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Detection of hypoxia |
US20050112120A1 (en)* | 1999-05-14 | 2005-05-26 | Waksal Harlan W. | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
US20060154334A1 (en)* | 2003-03-20 | 2006-07-13 | Joseph Tarnowski | Method of producing an antibody to epidermal growth factor receptor |
US20070264253A1 (en)* | 2004-03-19 | 2007-11-15 | Meilin Liu | Human Anti-Epidermal Growth Factor Receptor Antibody |
US20080008704A1 (en)* | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
US20080124801A1 (en)* | 2006-11-27 | 2008-05-29 | Stem Cell Sciences (Uk) Ltd. | Pluripotent cell growth media |
US20080171050A1 (en)* | 2000-08-09 | 2008-07-17 | Imclone Systems Inc. | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
WO2009009407A1 (en)* | 2007-07-06 | 2009-01-15 | Smithkline Beecham Corporation | Antibody formulations |
US20090297509A1 (en)* | 1998-05-15 | 2009-12-03 | Imclone Systems Incorporated | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
US20140255993A1 (en)* | 2011-07-01 | 2014-09-11 | Amgen Inc. | Mammalian cell culture |
EP2873422A4 (en)* | 2012-07-10 | 2015-12-30 | Takeda Pharmaceutical | PHARMACEUTICAL PREPARATION FOR INJECTION |
US10119117B2 (en) | 2016-01-28 | 2018-11-06 | Nanogen Pharmaceutical Biotechnology Co., Ltd | Universal, glycosylation enhancer, completely chemically defined medium formulation |
EP2841561B1 (en) | 2012-04-24 | 2019-01-16 | F.Hoffmann-La Roche Ag | Cell culture compositions and methods for polypeptide production |
CN111247239A (en)* | 2017-09-15 | 2020-06-05 | 生命技术公司 | Compositions and methods for culturing and expanding cells |
US12338290B2 (en) | 2016-08-15 | 2025-06-24 | Novartis Ag | Regimens and methods of treating multiple sclerosis using ofatumumab |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4636463A (en)* | 1984-04-05 | 1987-01-13 | Scripps Clinic And Research Foundation | Antibodies to human interleukin-2 induced by synthetic polypeptides |
US4652522A (en)* | 1983-07-05 | 1987-03-24 | The University Of Pennsylvania | Continuous lymphocyte cell lines, their production and use |
US4673649A (en)* | 1983-07-15 | 1987-06-16 | University Patents, Inc. | Process and defined medium for growth of human epidermal keratinocyte cells |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4652522A (en)* | 1983-07-05 | 1987-03-24 | The University Of Pennsylvania | Continuous lymphocyte cell lines, their production and use |
US4673649A (en)* | 1983-07-15 | 1987-06-16 | University Patents, Inc. | Process and defined medium for growth of human epidermal keratinocyte cells |
US4636463A (en)* | 1984-04-05 | 1987-01-13 | Scripps Clinic And Research Foundation | Antibodies to human interleukin-2 induced by synthetic polypeptides |
Title |
---|
Barnes, D. et al.: Methods for Growth of Cultured Cells . . . , Anal. Biochem. 102: 255 (1980).* |
Barnes, D. et al.: Serum Free Cell Culture . . . , Cell 22: 649 (1980).* |
Barnes, D. et al.: Serum-Free Cell Culture . . . , Cell 22: 649 (1980). |
Bettger, W. J. et al.: The Critical Role of Lipids . . . , in Growth of Cells in Hormonally . . . (1982).* |
Bottenstein, J. et al.: The Growth of Cells in Serum Free . . . , Basic Methods of . . . (1979).* |
Bottenstein, J. et al.: The Growth of Cells in Serum-Free . . . , Basic Methods of . . . (1979). |
Darfler, F. J. et al.: Growth of Lymphoid Cells . . . , in Methods for Serum Free Culture . . . (1984).* |
Darfler, F. J. et al.: Growth of Lymphoid Cells . . . , in Methods for Serum-Free Culture . . . (1984). |
Gibco catalog, p. 185 (1985).* |
Ham, R6: Importance of the Basal Nutrient Medium . . . , in Growth of Cells in Hormonally . . . (1982).* |
Hammond, S. L. et al.: Serum Free Growth of Human . . . , PNAS 81, 5435 (1984).* |
Hammond, S. L. et al.: Serum-Free Growth of Human . . . , PNAS 81, 5435 (1984). |
Hatzfeld, J. et al.: Specific Roles of Lipids, Transferrin . . . , in Growth of Cells in Hormonally . . . (1982).* |
Iscove, N. N.: Culture of Lymphocytes and Hemopoietic Cells . . . , in Methods for Serum Free Culture . . . (1984).* |
Iscove, N. N.: Culture of Lymphocytes and Hemopoietic Cells . . . , in Methods for Serum-Free Culture . . . (1984). |
Kawamoto, T. et al.: Development of a Serum Free Medium . . . , Anal. Biochem. 130: 445 (1983).* |
Kawamoto, T. et al.: Development of a Serum-Free Medium . . . , Anal. Biochem. 130: 445 (1983). |
Kovar, J. et al. (1984), Immunol. Lett. 7, 339 345.* |
Kovar, J. et al. (1984), Immunol. Lett. 7, 339-345. |
McHugh, Y. E. et al.: Serum Free Growth of Murine and Human . . . , Biotechniques Jun./Jul. (1983).* |
McHugh, Y. E. et al.: Serum-Free Growth of Murine and Human . . . , Biotechniques Jun./Jul. (1983). |
Mendelsohn, J. et al.: Culture of Human Lymphocytes . . . , in Methods for Serum Free Culture . . . (1984).* |
Mendelsohn, J. et al.: Culture of Human Lymphocytes . . . , in Methods for Serum-Free Culture . . . (1984). |
Mendelsohn, J. et al.: Proliferation of Normal Human Lymphocytes . . . , in Growth of Cells in Hormonally . . . (1982).* |
Mosier, D. E.: Primary in Vitro Antibody Responses by . . . , J. Immunol. 127: 1490 (1981).* |
Murakami, H. et al.: Growth of Hybridoma Cells in Serum Free . . . , PNAS 79: 1158 (1982).* |
Murakami, H. et al.: Growth of Hybridoma Cells in Serum-Free . . . , PNAS 79: 1158 (1982). |
Murakami, H.: Serum Free Cultivation of Plasmacytomas . . . in Methods for Serum Free Culture . . . (1984).* |
Murakami, H.: Serum-Free Cultivation of Plasmacytomas . . . in Methods for Serum-Free Culture . . . (1984). |
Promotional Material for Opti MEM by Gibco Laboratories (1985).* |
Promotional Material for Opti-MEM by Gibco Laboratories (1985). |
Promotional Material for PBM by JR Scientific.* |
Promotional Material for Ventrex HL 1 by Ventrex Laboratories (1984).* |
Promotional Material for Ventrex HL-1 by Ventrex Laboratories (1984). |
Spieker Polet, H. et al.: Requirement of a Combination of . . . , J. Immunol. 126: 949 (1981).* |
Spieker-Polet, H. et al.: Requirement of a Combination of . . . , J. Immunol. 126: 949 (1981). |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5063157A (en)* | 1988-01-18 | 1991-11-05 | Boehringer Mannheim Gmbh | Serum-free culture medium for mammalian cells |
US6048728A (en)* | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
US5122469A (en)* | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5397706A (en)* | 1991-11-06 | 1995-03-14 | Correa; Paulo N. | Serum-free basal and culture medium for hematopoietic and leukemia cells |
US6593140B1 (en) | 1992-07-24 | 2003-07-15 | Lonza Group, Ag | Animal cell culture |
US6855828B1 (en) | 1992-11-19 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Detection of hypoxia |
US5540908A (en)* | 1992-11-19 | 1996-07-30 | The Trustees Of The Univ. Of Pennsylvania | Detection of hypoxia with reagents containing 2-nitroimidazole compounds and methods of making such reagents |
US5843404A (en)* | 1992-11-19 | 1998-12-01 | Trustees Of The University Of Pennsylvania | Detection of hypoxia |
US6252087B1 (en) | 1992-11-19 | 2001-06-26 | The Trustees Of The University Of Pennsylvania | Nitroaromatic compounds for the detection of hypoxia |
US5405772A (en)* | 1993-06-18 | 1995-04-11 | Amgen Inc. | Medium for long-term proliferation and development of cells |
EP0719326A1 (en)* | 1993-08-23 | 1996-07-03 | Baxter International Inc. | $i(IN VITRO) GROWTH OF NEUTROPHIL AND MEGAKARYOCYTE PRECURSORS IN SERUM-FREE MEDIA |
US6010697A (en)* | 1993-08-23 | 2000-01-04 | Nexell Therapeutics, Inc. | Infusion of neutrophil precursors for treatment of neutropenia |
US5846529A (en)* | 1993-08-23 | 1998-12-08 | Nexell Therapeutics, Inc. | Infusion of neutrophil precursors for treatment of neutropenia |
US6037174A (en)* | 1993-08-23 | 2000-03-14 | Nexell Therapeutics, Inc. | Preparation of serum-free suspensions of human hematopoietic cells or precursor cells |
WO1995024467A1 (en)* | 1994-03-09 | 1995-09-14 | Cellco, Inc. | Serum-free production of packaged viral vector |
US5498537A (en)* | 1994-03-09 | 1996-03-12 | Cellco, Inc. | Serum-free production of packaged viral vector |
US20090099339A1 (en)* | 1995-06-07 | 2009-04-16 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
US20040006212A1 (en)* | 1995-06-07 | 2004-01-08 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
US20050026974A1 (en)* | 1996-02-08 | 2005-02-03 | Trustees Of The University Of Pennsylvania | Detection of hypoxia |
US20030224001A1 (en)* | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
US20090297509A1 (en)* | 1998-05-15 | 2009-12-03 | Imclone Systems Incorporated | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
US6051401A (en)* | 1998-07-28 | 2000-04-18 | Bayer Corporation | Methods and constructs for protein expression |
AU765584B2 (en)* | 1998-09-17 | 2003-09-25 | Eli Lilly And Company | Protein formulations |
US6440930B1 (en)* | 1998-09-17 | 2002-08-27 | Eli Lilly And Company | Protein formulations |
WO2000015224A1 (en)* | 1998-09-17 | 2000-03-23 | Eli Lilly And Company | Protein formulations |
US20050112120A1 (en)* | 1999-05-14 | 2005-05-26 | Waksal Harlan W. | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
US20080171050A1 (en)* | 2000-08-09 | 2008-07-17 | Imclone Systems Inc. | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
US6573237B2 (en) | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
US20080008704A1 (en)* | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
US20060154334A1 (en)* | 2003-03-20 | 2006-07-13 | Joseph Tarnowski | Method of producing an antibody to epidermal growth factor receptor |
US20070264253A1 (en)* | 2004-03-19 | 2007-11-15 | Meilin Liu | Human Anti-Epidermal Growth Factor Receptor Antibody |
US7598350B2 (en) | 2004-03-19 | 2009-10-06 | Imclone Llc | Human anti-epidermal growth factor receptor antibody |
US20080124801A1 (en)* | 2006-11-27 | 2008-05-29 | Stem Cell Sciences (Uk) Ltd. | Pluripotent cell growth media |
WO2008065381A1 (en)* | 2006-11-27 | 2008-06-05 | Stem Cell Sciences (Uk) Ltd | Pluripotent cell growth media |
AU2008275278B2 (en)* | 2007-07-06 | 2011-04-14 | Novartis Ag | Antibody formulations |
US20110020328A1 (en)* | 2007-07-06 | 2011-01-27 | Glaxosmithkline Llc | Antibody formulations |
WO2009009407A1 (en)* | 2007-07-06 | 2009-01-15 | Smithkline Beecham Corporation | Antibody formulations |
EA017994B1 (en)* | 2007-07-06 | 2013-04-30 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Antibody formulations |
US11634476B2 (en) | 2011-07-01 | 2023-04-25 | Amgen Inc. | Mammalian cell culture |
US11292829B2 (en)* | 2011-07-01 | 2022-04-05 | Amgen Inc. | Mammalian cell culture |
US20140255993A1 (en)* | 2011-07-01 | 2014-09-11 | Amgen Inc. | Mammalian cell culture |
US11673941B2 (en) | 2011-07-01 | 2023-06-13 | Amgen Inc. | Mammalian cell culture |
US11685772B2 (en) | 2011-07-01 | 2023-06-27 | Amgen Inc. | Mammalian cell culture |
US11827692B2 (en) | 2011-07-01 | 2023-11-28 | Amgen Inc. | Mammalian cell culture |
EP2841561B1 (en) | 2012-04-24 | 2019-01-16 | F.Hoffmann-La Roche Ag | Cell culture compositions and methods for polypeptide production |
EP2873422A4 (en)* | 2012-07-10 | 2015-12-30 | Takeda Pharmaceutical | PHARMACEUTICAL PREPARATION FOR INJECTION |
US10119117B2 (en) | 2016-01-28 | 2018-11-06 | Nanogen Pharmaceutical Biotechnology Co., Ltd | Universal, glycosylation enhancer, completely chemically defined medium formulation |
US12338290B2 (en) | 2016-08-15 | 2025-06-24 | Novartis Ag | Regimens and methods of treating multiple sclerosis using ofatumumab |
CN111247239A (en)* | 2017-09-15 | 2020-06-05 | 生命技术公司 | Compositions and methods for culturing and expanding cells |
Publication | Publication Date | Title |
---|---|---|
US4816401A (en) | Serum free cell culture medium | |
EP0283942B1 (en) | Basal nutrient medium for cell culture | |
US6048728A (en) | Cell culture medium for enhanced cell growth, culture longevity, and product expression | |
US5045468A (en) | Protein-free culture medium which promotes hybridoma growth | |
AU2019202259B2 (en) | Cell culture compositions and methods for polypeptide production | |
US5324656A (en) | Media for normal human muscle satellite cells | |
AU632065B2 (en) | Cell culture medium for enhanced cell growth, culture longevity and product expression | |
US5328844A (en) | Culture media for mammalian cells | |
US5135866A (en) | Very low protein nutrient medium for cell culture | |
Iscove | Culture of lymphocytes and hemopoietic cells in serum-free medium | |
Shacter | Serum-free medium for growth factor-dependent and-independent plasmacytomas and hybridomas | |
FR2600076A1 (en) | CULTURE MEDIUM COMPRISING HUMAN ALBUMIN, PROCESS FOR PREPARING A PRODUCT INJECTABLE THEREFROM, PRODUCT OBTAINED AND USE THEREOF, COMPOSITION OBTAINED | |
EP0659880B1 (en) | Medium for culturing animal cells or antibody-producing cells | |
Darfler | A protein-free medium for the growth of hybridomas and other cells of the immune system | |
CN1087778C (en) | Hybridizing tumour cell non-serum culture medium | |
CA2091443A1 (en) | Medium for culture of mammalian cells | |
McKENZIE et al. | Effects of mammalian insulin on metabolism, growth, and morphology of a wall-less strain of Neurospora crassa | |
Keen | The culture of rat myeloma and rat hybridoma cells in a protein-free medium | |
Kim et al. | Development of a serum-free medium for the production of humanized antibody from Chinese hamster ovary cells using a statistical design | |
US20150267237A1 (en) | Cell culture compositions and methods for polypeptide production | |
CA2186608A1 (en) | Serum-free medium supplement | |
CN118325843A (en) | Low-protein serum-free culture medium suitable for hybridoma cell suspension culture and monoclonal antibody production and application thereof | |
JPH0120867B2 (en) | ||
CA2001550A1 (en) | Very low protein nutrient medium for cell culture | |
CA2534286C (en) | Myeloma cell culture in transferrin-free low iron medium |
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment | Owner name:UNIVERSITY THE, ROCHESTER, NEW YORK, A CORP OF NEW Free format text:ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:TAUPIER, MARY ANN;LORD, EDITH M.;REEL/FRAME:004454/0950 Effective date:19850909 | |
STCF | Information on status: patent grant | Free format text:PATENTED CASE | |
FPAY | Fee payment | Year of fee payment:4 | |
FPAY | Fee payment | Year of fee payment:8 | |
FEPP | Fee payment procedure | Free format text:PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY | |
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment | Year of fee payment:12 | |
SULP | Surcharge for late payment | Year of fee payment:11 | |
AS | Assignment | Owner name:NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text:CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF ROCHESTER;REEL/FRAME:021561/0770 Effective date:19890428 |